Financials

Company Profile

ATech (Parent) Resolution Corp., formerly Akoustis Technologies, Inc., is not engaged in any business operating activity. The Company has no assets.

Employees

Sector

08-19	Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says	MT
08-19	Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target	MT
08-19	BMO Capital Initiates Akoustis Technologies at Outperform	MT
08-13	Earnings Flash (AKTS) Aktis Oncology, Inc. Reports Q2 Revenue $3.4M, vs. FactSet Est of $2.1M	MT
07-10	Aktis Oncology Insider Sold Shares Worth $1,388,701, According to a Recent SEC Filing	MT
07-10	Aktis Oncology Insider Sold Shares Worth $1,387,558, According to a Recent SEC Filing	MT
06-16	Raymond James Initiates Aktis Oncology at Strong Buy With $40 Price Target	MT
05-22	Top Premarket Gainers	MT
05-11	Earnings Flash (AKTS) Aktis Oncology, Inc. Reports Q1 Revenue $3.2M	MT
04-29	William Blair Initiates Aktis Oncology at Outperform	MT
03-30	Aktis Oncology Receives US FDA Approval for AKY-2519 Investigational New Drug Applications	MT
03-09	HC Wainwright Initiates Aktis Oncology at Buy With $30 Price Target	MT
02-24	Aktis Oncology Says US FDA Grants Fast Track Designation to AKY-1189 for Urothelial Cancer	MT

08-19	Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says	MT
08-19	Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target	MT
08-19	BMO Capital Initiates Akoustis Technologies at Outperform	MT
06-16	Raymond James Initiates Aktis Oncology at Strong Buy With $40 Price Target	MT
04-29	William Blair Initiates Aktis Oncology at Outperform	MT

24-12-16	Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process	GL
24-12-16	Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process	BU
24-12-02	Akoustis Technologies : Material Event Form 8 K	PU
24-11-15	Akoustis: Fiscal Q1 Earnings Snapshot	AQ
24-10-28	Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG	AQ

Manager	Title	Age	Since
Robert Dry COO	Chief Operating Officer	-	-
Mary Winters COO	Chief Operating Officer	-	-
Colin Hunt SAM	Sales & Marketing	-	2020-06-01

Director	Title	Age	Since
Jerry Neal CHM	Chairman	82	2016-03-13
Arthur Geiss CHM	Chairman	73	2016-03-13
Jill Frizzley BRD	Director/Board Member	50	2024-08-06

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AKOUSTIS TECHNOLOGIES INC	+12.50%	-10.00%	-	-	155
CHURCHILL CAPITAL CORP XI	+3.55%	-14.65%	-	-	812M
CENTIEL AG	-4.49%	-9.38%	+287.22%	-75.28%	658M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	0.00%	+0.10%	-	-	646M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.39%	+0.29%	-	-	600M
CHURCHILL CAPITAL CORP XII	-0.74%	-0.33%	-	-	595M
CANTOR EQUITY PARTNERS IV, INC.	-0.48%	-0.77%	+2.02%	-	591M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	+0.52%	+1.21%	-	-	578M
CHURCHILL CAPITAL CORP XIII	0.00%	+0.67%	-	-	508M
Average	+1.16%	-2.59%	+144.62%	-75.28%	623.41M
Weighted average by Cap.	-0.15%	-3.22%	+152.25%	-75.28%